Misonix has launched the Sonablate 500 prostate cancer treatment system in Western Europe, Eastern Europe, and Russia.
Sonablate 500 employs high-intensity focused ultrasound for the treatment of prostate cancer, enlarged prostate, and other prostatic tumors, according to the Farmingdale, NY-based vendor. Misonix has exclusive distribution rights for Sonablate 500, which is licensed from Focus Surgery of Indianapolis
By AuntMinnie.com staff writersMarch 31, 2004
Related Reading
Misonix to distribute Sonablate 500 in Europe, March 2, 2004
Misonix continues gains in Q2, January 29, 2004
Misonix shows Q1 uptick, October 30, 2003
Misonix gets approvals for Sonablate 500, August 10, 2001
Misonix hires Berger as scientific and industrial VP, May 18, 2001
Copyright © 2004 AuntMinnie.com